- Home
- ADV vs RLAY Comparison
ADV vs RLAY Comparison
Compare ADV & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADV
- RLAY
- Stock Information
- Founded
- ADV 1987
- RLAY 2015
- Country
- ADV United States
- RLAY United States
- Employees
- ADV N/A
- RLAY N/A
- Industry
- ADV Business Services
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADV Consumer Discretionary
- RLAY Health Care
- Exchange
- ADV Nasdaq
- RLAY Nasdaq
- Market Cap
- ADV 415.1M
- RLAY 490.3M
- IPO Year
- ADV N/A
- RLAY 2020
- Fundamental
- Price
- ADV $1.63
- RLAY $3.18
- Analyst Decision
- ADV Strong Buy
- RLAY Strong Buy
- Analyst Count
- ADV 1
- RLAY 11
- Target Price
- ADV $2.50
- RLAY $18.40
- AVG Volume (30 Days)
- ADV 788.6K
- RLAY 1.6M
- Earning Date
- ADV 08-06-2025
- RLAY 08-05-2025
- Dividend Yield
- ADV N/A
- RLAY N/A
- EPS Growth
- ADV N/A
- RLAY N/A
- EPS
- ADV N/A
- RLAY N/A
- Revenue
- ADV $3,526,704,000.00
- RLAY $7,679,000.00
- Revenue This Year
- ADV N/A
- RLAY $14.31
- Revenue Next Year
- ADV N/A
- RLAY N/A
- P/E Ratio
- ADV N/A
- RLAY N/A
- Revenue Growth
- ADV N/A
- RLAY N/A
- 52 Week Low
- ADV $1.04
- RLAY $1.78
- 52 Week High
- ADV $4.16
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- ADV 62.18
- RLAY 55.48
- Support Level
- ADV $1.42
- RLAY $2.98
- Resistance Level
- ADV $1.70
- RLAY $3.48
- Average True Range (ATR)
- ADV 0.15
- RLAY 0.25
- MACD
- ADV 0.03
- RLAY -0.00
- Stochastic Oscillator
- ADV 81.36
- RLAY 58.45
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).